| Literature DB >> 32825736 |
Mohd Zurairie Mohd Zubir1, Samantha Holloway1, Norhayati Mohd Noor2.
Abstract
BACKGROUND: It is estimated that 2% of the population in developing countries suffer from a chronic wound, making it a hidden phenomenon that is increasing as populations age. The ease of access to maggot therapy has made it increasingly attractive for implementation. This study aimed to explore the effectiveness of maggot therapy as compared to hydrogel dressings in the healing of chronic wounds.Entities:
Keywords: disinfection; granulation tissue; hydrogel dressings; maggots; pain; wounds
Mesh:
Year: 2020 PMID: 32825736 PMCID: PMC7504313 DOI: 10.3390/ijerph17176103
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart.
Summary of included studies.
| Year | Type of Wound | Number of Participants | Intervention and Control | Outcome | Follow-Up | Level of Evidence |
|---|---|---|---|---|---|---|
| Sherman [ | Pressure ulcers | MT (loose) = 43 | MT vs. “conventional | Debridement | 17–19 weeks | Level III-2 |
| Sherman [ | Diabetic foot and leg ulcers | MT (loose) = 14 | MT vs. “conventional | Debridement | 8 weeks | Level III-2 |
| Dumville et al. [ | Venous or mixed | MT 180 | MT vs. hydrogel | Complete debridement | 6–12 months | Level II |
| Opletalová et al. [ | Venous leg ulcers (ABPI | MT (bagged) = 51 | MT vs. “conventional | Debridement | 30 days | Level II |
| Mudge et al. [ | Venous or mixed leg ulcers (ABPI | MDT (bagged) = 46 | MT vs. hydrogel | Debridement | 28–35 days | Level II |
MT, maggot therapy; ABPI, Ankle Brachial Pressure Index; Level II, evidence obtained from at least one properly-designed randomised controlled trial; Level III-2, evidence obtained from comparative studies with historical control, two or more single arm studies, or interrupted time series without a parallel control group.
Summary of Critical Appraisal Skills Programme checklist for the studies included.
| CASP Checklist | Sherman [ | Sherman [ | Dumville et al. [ | Opletalová et al. [ | Mudge et al. [ |
|---|---|---|---|---|---|
| Are the results valid? | |||||
| Focused issue 1 | Yes | Yes | Yes | Yes | Yes |
| Randomization 2 | No | No | Yes | Yes | Yes |
| Eligibility 3 | Yes | Yes | Yes | Yes | Yes |
| Blinding 4 | No | No | No | Yes | Cannot tell |
| Baseline homogeneity 5 | Cannot tell | Cannot tell | No | Yes | Yes |
| Equal treatment 6 | Cannot tell | Cannot tell | Yes | No | Yes |
| Will the results help locally? | |||||
| Application of results 7 | Yes | Yes | Yes | Yes | Yes |
| Important outcomes 8 | Yes | Yes | Yes | Yes | Yes |
| Benefits 9 | Yes | Yes | Yes | Yes | Yes |
CASP, Critical Appraisal Skills Programme. 1 Did the trial address a clearly focused issue? 2 Was the assignment of patients to treatments randomized? 3 Were all of the patients who entered the trial properly accounted for at its conclusion? 4 Were patients, health workers and study personnel ‘blind’ to treatment? 5 Were the groups similar at the start of the trial? 6 Aside from the experimental intervention, were the groups treated equally? 7 Can the results be applied to the local population, or in your context? 8 Were all clinically important outcomes considered? 9 Are the benefits worth the harms and costs?
Figure 2Risk of bias graph.
Figure 3Risk of bias summary. The green color indicates low risk of bias, yellow color indicates unclear risk of bias and red color indicates high risk of bias.
Summary of outcomes.
| Study Objectives | Sherman [ | Sherman [ | Dumville et al. [ | Opletalová et al. [ | Mudge et al. [ |
|---|---|---|---|---|---|
| Debridement of the non-viable tissue | Significant | Significant ( | Significant | Significant | Significant |
| Disinfection of bacterial growth | Not studied | Not studied | Not significant | Not significant | Not significant |
| Growth of granulation tissue | Significant | Significant | Not studied | Not studied | Not significant |
| Reduction on wound surface area | Significant | Significant | Not studied | Significant | Not studied |
| Complete healing | Not significant | Not significant | Not significant | Not studied | Not studied |
| Adverse events | Not significant | Not significant | MT significantly more painful | Not significant | MT significantly more painful |
| Duration of healing | Within 12 weeks | Within 15 weeks | Within 236 days | Not studied | Not studied |